POTE ankyrin domain family member A (gene/pseudogene)Genealiases: A26A1 · CT104.3 · POTE-8 · POTE8
Q-omics provides the consensus-scored POTEA profile across patient tissues and cancer cell-line models. POTEA expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, POTEA is differentially expressed in 3, with the highest sampling consensus in ESCA. Additionally, POTEA RNA expression shows 5,857 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, ESCA, and STAD as cancer lineages where POTEA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POTEA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POTEA survival associations across molecular data types. POTEA RNA expression shows survival associations in the most cancer types (11), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POTEA RNA expression–survival associations across cancer types. High POTEA expression shows unfavorable associations in KICH, ACC, UCS and CHOL, but favorable associations in ESCA and SKCM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for POTEA RNA expression.
This table summarizes POTEA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for POTEA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POTEA shows higher tumor expression in ESCA, THCA and HNSC. The ESCA box plot shows higher POTEA RNA expression in tumor versus normal tissue (log2 FC = +0.035, t-test p = .019).
This table shows molecular features associated with POTEA in patient tissues and cancer cell lines. In patient samples, POTEA shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, POTEA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
